JP2022536755A5 - - Google Patents

Info

Publication number
JP2022536755A5
JP2022536755A5 JP2021573832A JP2021573832A JP2022536755A5 JP 2022536755 A5 JP2022536755 A5 JP 2022536755A5 JP 2021573832 A JP2021573832 A JP 2021573832A JP 2021573832 A JP2021573832 A JP 2021573832A JP 2022536755 A5 JP2022536755 A5 JP 2022536755A5
Authority
JP
Japan
Prior art keywords
substituted
independently selected
alkyl
group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037403 external-priority patent/WO2020252240A1/en
Publication of JP2022536755A publication Critical patent/JP2022536755A/ja
Publication of JP2022536755A5 publication Critical patent/JP2022536755A5/ja
Priority to JP2024208554A priority Critical patent/JP2025037981A/ja
Pending legal-status Critical Current

Links

JP2021573832A 2019-06-14 2020-06-12 Sting活性に関連する状態を治療するための化合物および組成物 Pending JP2022536755A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024208554A JP2025037981A (ja) 2019-06-14 2024-11-29 Sting活性に関連する状態を治療するための化合物および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861714P 2019-06-14 2019-06-14
US62/861,714 2019-06-14
US201962955924P 2019-12-31 2019-12-31
US62/955,924 2019-12-31
PCT/US2020/037403 WO2020252240A1 (en) 2019-06-14 2020-06-12 Compounds and compositions for treating conditions associated with sting activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024208554A Division JP2025037981A (ja) 2019-06-14 2024-11-29 Sting活性に関連する状態を治療するための化合物および組成物

Publications (2)

Publication Number Publication Date
JP2022536755A JP2022536755A (ja) 2022-08-18
JP2022536755A5 true JP2022536755A5 (cg-RX-API-DMAC7.html) 2023-06-19

Family

ID=71465411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573832A Pending JP2022536755A (ja) 2019-06-14 2020-06-12 Sting活性に関連する状態を治療するための化合物および組成物
JP2024208554A Pending JP2025037981A (ja) 2019-06-14 2024-11-29 Sting活性に関連する状態を治療するための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024208554A Pending JP2025037981A (ja) 2019-06-14 2024-11-29 Sting活性に関連する状態を治療するための化合物および組成物

Country Status (8)

Country Link
US (1) US20230092163A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983383A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022536755A (cg-RX-API-DMAC7.html)
MA (1) MA56193A (cg-RX-API-DMAC7.html)
PY (1) PY2026348A (cg-RX-API-DMAC7.html)
TW (1) TWI873145B (cg-RX-API-DMAC7.html)
UY (1) UY38751A (cg-RX-API-DMAC7.html)
WO (1) WO2020252240A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
JP2022517797A (ja) * 2019-01-17 2022-03-10 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
US20240051970A1 (en) * 2020-12-16 2024-02-15 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024500877A (ja) * 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240122903A1 (en) 2020-12-22 2024-04-18 Ifm Due Inc. Methods of treating cancer
JP2024504002A (ja) * 2020-12-22 2024-01-30 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-(吲哚-5-基)芳香杂环酰胺类化合物及其制备方法和用途
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN115710255B (zh) * 2021-08-23 2025-05-06 上海交通大学 一类含有苯并杂环取代的脲类衍生物及其制备和用途
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
WO2024151919A1 (en) * 2023-01-13 2024-07-18 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024233603A1 (en) * 2023-05-09 2024-11-14 Icagen, Llc Novel carboxamide derivatives
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating activity of microrna-124
WO2025079045A1 (en) * 2023-10-12 2025-04-17 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
WO2025153990A1 (en) * 2024-01-19 2025-07-24 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
WO2025188646A1 (en) * 2024-03-04 2025-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for treating cancer
CN120794982A (zh) * 2024-05-14 2025-10-17 中国药科大学 吡唑类sting抑制剂及其医药用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500551A (ja) * 1990-09-13 1994-01-20 ビーチャム・グループ・パブリック・リミテッド・カンパニー 5ht受容体アンタゴニストとしてのインドールウレア
US5439906A (en) * 1993-11-22 1995-08-08 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
DE60013250T2 (de) * 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP2397478A1 (en) * 2005-01-14 2011-12-21 CGI Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity.
RU2008110908A (ru) * 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
CN101583598B (zh) * 2007-01-15 2012-09-12 参天制药株式会社 具有IκB激酶β抑制活性的新型吲哚衍生物
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
AU2014340269B2 (en) 2013-10-21 2018-06-21 Drexel University Use of STING agonists to treat chronic hepatitis B virus infection
BR112018001424B1 (pt) * 2015-07-30 2024-02-06 Calgent Biotechnology Co., Ltd Compostos, composição farmacêutica e usos de um composto
US20170146519A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
CN111132972B (zh) * 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
AU2018325445A1 (en) * 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
EP3556362A1 (en) * 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
TWI873098B (zh) * 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
CN112823151B (zh) * 2018-07-03 2024-11-15 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
CN109734677A (zh) * 2019-03-07 2019-05-10 四川大学 抑制组蛋白赖氨酸甲基转移酶nsd2的小分子化合物及其应用

Similar Documents

Publication Publication Date Title
JP6499077B2 (ja) アルツハイマー病と関連疾患の治療のための併用療法
JP2026048714A (ja) 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸
JP2024509818A5 (cg-RX-API-DMAC7.html)
JP6189989B2 (ja) C5aRアンタゴニスト
JP2023509422A5 (cg-RX-API-DMAC7.html)
JP2019507793A5 (cg-RX-API-DMAC7.html)
JP2025510074A5 (cg-RX-API-DMAC7.html)
US12391664B2 (en) GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
PT2046740E (pt) Compostos com atividade antagonista do crth2
RU2004119037A (ru) Гетероциклические соединения и способы применения
JP2008513515A5 (cg-RX-API-DMAC7.html)
JP2023503962A5 (cg-RX-API-DMAC7.html)
RU2005139525A (ru) N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
JP2023520396A5 (cg-RX-API-DMAC7.html)
US20230192626A1 (en) Novel soluble epoxide hydrolase inhibitors and method of use thereof
JP7440486B2 (ja) チアジアジン誘導体
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2024502473A5 (cg-RX-API-DMAC7.html)
JP2010520884A5 (cg-RX-API-DMAC7.html)
JP2007509104A (ja) 複素環式化合物
CN111201232A (zh) Atf3诱导化合物
JP2022105013A (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
CN101384549B (zh) 吡咯衍生物或其盐
JP2021534254A5 (ja) 心臓弁疾患を治療するための医薬組成物
JPS61227567A (ja) 1,4−ジヒドロピリジン誘導体